All Publications


  • Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma. Nature communications Fernandez, E. G., Mai, W. X., Song, K., Bayley, N. A., Kim, J., Zhu, H., Pioso, M., Young, P., Andrasz, C. L., Cadet, D., Liau, L. M., Li, G., Yong, W. H., Rodriguez, F. J., Dixon, S. J., Souers, A. J., Li, J. J., Graeber, T. G., Cloughesy, T. F., Nathanson, D. A. 2024; 15 (1): 10089

    Abstract

    Genomic profiling often fails to predict therapeutic outcomes in cancer. This failure is, in part, due to a myriad of genetic alterations and the plasticity of cancer signaling networks. Functional profiling, which ascertains signaling dynamics, is an alternative method to anticipate drug responses. It is unclear whether integrating genomic and functional features of solid tumours can provide unique insight into therapeutic vulnerabilities. We perform combined molecular and functional characterization, via BH3 profiling of the intrinsic apoptotic machinery, in glioma patient samples and derivative models. We identify that standard-of-care therapy rapidly rewires apoptotic signaling in a genotype-specific manner, revealing targetable apoptotic vulnerabilities in gliomas containing specific molecular features (e.g., TP53 WT). However, integration of BH3 profiling reveals high mitochondrial priming is also required to induce glioma apoptosis. Accordingly, a machine-learning approach identifies a composite molecular and functional signature that best predicts responses of diverse intracranial glioma models to standard-of-care therapies combined with ABBV-155, a clinical drug targeting intrinsic apoptosis. This work demonstrates how complementary functional and molecular data can robustly predict therapy-induced cell death.

    View details for DOI 10.1038/s41467-024-54138-9

    View details for PubMedID 39572533

    View details for PubMedCentralID 2263014